SCHEMBL5267929

SCHEMBL5267929

Fc1cc(OCc2ccccc2)c(Br)cc1Cl

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MRGPRX4 Q96LA9 4/20 0.46
RAB9A P51151 3/20 0.46
SMN1; SMN2 Q16637 3/20 0.46
KDM1A O60341 3/20 0.45
NPC1 O15118 3/20 0.43
NFKB1 P19838 2/20 0.43
NFKB2 Q00653 2/20 0.43
RELA Q04206 2/20 0.43
MAPK14 Q16539 3/20 0.42
HTR2A P28223 1/20 0.42
HTR2C P28335 1/20 0.42
MAOB P27338 1/20 0.41
THRA P10827 1/20 0.41
THRB P10828 1/20 0.41
MAPT P10636 1/20 0.41
MAPK1 P28482 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
FFAR1 O14842 1/20 0.41
FFAR4 Q5NUL3 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20922980 0.94 RAB9A (0.46) MRGPRX4RAB9ASMN1; SMN2KDM1ANPC1
SCHEMBL18556063 0.88 RAB9A (0.46) MRGPRX4RAB9ASMN1; SMN2KDM1ANPC1
SCHEMBL16636496 0.87 RAB9A (0.50) MRGPRX4RAB9ASMN1; SMN2KDM1ANPC1
SCHEMBL31166845 0.82 RAB9A (0.49) MRGPRX4RAB9ASMN1; SMN2KDM1ANPC1
SCHEMBL416139 0.79 KDM1A (0.48) MRGPRX4RAB9ASMN1; SMN2KDM1ANPC1
SCHEMBL19679217 0.78 PTGER1 (0.55) MRGPRX4RAB9ASMN1; SMN2NPC1NFKB1
SCHEMBL31110673 0.78 MAOB (0.49) MRGPRX4RAB9ASMN1; SMN2KDM1AHTR2A
SCHEMBL31110667 0.78 MAOB (0.49) MRGPRX4RAB9ASMN1; SMN2KDM1AHTR2A
SCHEMBL207723 0.78 SMN1; SMN2 (0.49) RAB9ASMN1; SMN2KDM1ANPC1MAOB
SCHEMBL31611455 0.77 RAB9A (0.48) MRGPRX4RAB9ASMN1; SMN2KDM1ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1456180-B1 3-(2,4)DIHYDROXYPHENYL-4-PHENYLPYRAZOLES AND THEIR MEDICAL USE VERNALIS CAMBRIDGE LTD (GB) 2007-10-03 EP disclosed
EP-1456180-B1 3-(2,4)DIHYDROXYPHENYL-4-PHENYLPYRAZOLES AND THEIR MEDICAL USE VERNALIS CAMBRIDGE LTD (GB) 2007-10-03 EP disclosed
US-7247734-B2 3,4-diarylpyrazoles and their use in the therapy of cancer VERNALIS (CAMBRIDGE) LIMITED (GB) 2007-07-24 US disclosed
US-7247734-B2 3,4-diarylpyrazoles and their use in the therapy of cancer VERNALIS (CAMBRIDGE) LIMITED (GB) 2007-07-24 US disclosed
US-20050222230-A1 3,4-diarylpyrazoles and their use in the therapy of cancer VERNALIS (CAMBRIDGE) LIMITED (GB) 2005-10-06 US disclosed
EP-1456180-A1 3,4-DIARYLPYRAZOLES AND THEIR USE IN THE THERAPY OF CANCER Vernalis (Oxford) Ltd (GB) 2004-09-15 EP disclosed
WO-2003055860-A1 3,4-DIARYLPYRAZOLES AND THEIR USE IN THE THERAPY OF CANCER VERNALIS (CAMBRIDGE) LIMITED (GB) 2003-07-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050222230-A1 3,4-diarylpyrazoles and their use in the therapy of cancer HSP90AB1, HSP90AA1, HSP90AB2P MRGPRX4 1917/4885RAB9A 3155/4885SMN1; SMN2 4757/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.